VentriPoint Diagnostics (VPT) Q2 2025 earnings summary

Executive summary

• Focused on development and commercialization of heart disease diagnostic tools, with 75% of sales in Europe.

• Accumulated deficit reached $60.7M as of June 30, 2025, with ongoing material uncertainty about going concern.

Financial highlights

• Revenue for the six months ended June 30, 2025 was $30,665, down from $71,320 year-over-year.

• Net loss for the six months ended June 30, 2025 was $2,248,407, compared to $2,608,879 in the prior year.

• Cash and cash equivalents increased to $248,818 as of June 30, 2025, from $60,547 at December 31, 2024.

• Negative cash flow from operating activities was $859,853 for the six months ended June 30, 2025.

Outlook and guidance

• Plans to raise approximately $500,000 by the end of 2025 to support ongoing operations.

• Announced a non-brokered private placement of up to $500,000 in convertible debenture units post-period.